公开(公告)号：DK2555754T3

公开(公告)日：2016-04-18

申请号：DK11714625

申请日：2011-04-07

Applicant: VERTEX PHARMA

Inventor： KESHAVARZ-SHOKRI ALI ,  ZHANG BEILI ,  KRAWIEC MARIUSZ

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  C07D213/75 ,  C07D405/12 ,  C07D405/14

公开(公告)号：UA102534C2

公开(公告)日：2013-07-25

申请号：UAA201008467

申请日：2008-12-04

Applicant: VERTEX PHARMA

Inventor： KESHAVARZ-SHOKRI ALI ,  ZHANG BEILI ,  KRAWIEC MARIUSZ

IPC: C07D405/12 ,  A61K31/443 ,  A61P11/00

Abstract: Изобретениекасаетсякристаллическойформысвободноготвердоговещества, 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойнойкислоты (Форма 1) формулы 1, фармацевтическихкомпозиций, которыесодержатданноевещество, иеепримененияв способахлечения.

公开(公告)号：ZA201207947B

公开(公告)日：2013-06-26

申请号：ZA201207947

申请日：2012-10-22

Applicant: VERTEX PHARMA

Inventor： KESHAVARZ-SHOKRI ALI ,  KRAWIEC MARIUSZ ,  ZHANG BEILI

IPC: A61K20060101 ,  C07D20060101

公开(公告)号：AU2011242457A1

公开(公告)日：2012-11-08

申请号：AU2011242457

申请日：2011-04-22

Applicant: VERTEX PHARMA

Inventor： VAN GOOR FREDRICK F ,  ALARGOVA ROSSITZA GUEORGUIEVA ,  ALCACIO TIM EDWARD ,  BINCH HAYLEY MARIE ,  BOTFIELD MARTYN CURTIS ,  FANNING LEV TYLER DEWEY ,  GROOTENHUIS PETER DIEDERIK JAN ,  HURLEY DENNIS JAMES ,  KADIYALA IRINA NIKOLAEVNA ,  KAUSHIK RITU ROHIT ,  KESHAVARZ-SHOKRI ALI ,  KRAWIEC MARIUSZ ,  LEE ELAINE CHUNGMIN ,  LUISI BRIAN ,  MEDEK ALES ,  NUMA MEHDI ,  SHETH URVI JAGDISHBHAI ,  SILINA ALINA ,  VERWIJS MARINUS JACOBUS ,  YANG XIAOQING ,  YOUNG CHRISTOPHER RYAN ,  ZAMAN NOREEN TASNEEM ,  ZHANG BEILI ,  ZHANG YUEGANG ,  ZLOKARNIK GREGOR

IPC: A61K31/4704 ,  A61K31/404 ,  A61K31/443

Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.(Formula I), (Formula II), (Formula III).

公开(公告)号：AU2011237494A1

公开(公告)日：2012-11-01

申请号：AU2011237494

申请日：2011-04-07

Applicant: VERTEX PHARMA

Inventor： KESHAVARZ-SHOKRI ALI ,  ZHANG BEILI ,  KRAWIEC MARIUSZ

IPC: C07D405/12

Abstract: The present invention relates to a substantially a solid form of 3-(6-(l-(2,2- difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1, Solvate Form A and Compound 1, HCl Salt Form A), processes for making such forms, pharmaceutical compositions thereof, and methods of treatment therewith.

公开(公告)号：CA3016080A1

公开(公告)日：2011-09-29

申请号：CA3016080

申请日：2011-03-25

Applicant: VERTEX PHARMA

Inventor： ALCACIO TIM EDWARD ,  KESHAVARZ-SHOKRI ALI ,  KRAWIEC MARIUSZ ,  LEE ELAINE CHUNGMIN ,  ZHANG BEILI ,  ZHANG YUEGANG

IPC: A61K31/404 ,  A61K9/10 ,  A61K47/38 ,  A61P3/00 ,  A61P11/00

Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.

公开(公告)号：CA2794559A1

公开(公告)日：2011-09-29

申请号：CA2794559

申请日：2011-03-25

Applicant: VERTEX PHARMA

Inventor： KESHAVARZ-SHOKRI ALI ,  ZHANG BEILI ,  ALCACIO TIM EDWARD ,  LEE ELAINE CHUNGMIN ,  ZHANG YUEGANG ,  KRAWIEC MARIUSZ

IPC: C07D405/12 ,  A61K31/404 ,  A61P11/00

Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2- methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.

公开(公告)号：MX388103B

公开(公告)日：2025-03-19

申请号：MX2019006637

申请日：2019-06-06

Applicant: VERTEX PHARMA

Inventor： ABELA ALEXANDER RUSSELL ,  KESHAVARZ-SHOKRI ALI ,  TERMIN ANDREAS P ,  GULEVICH ANTON ,  HSIA CLARA KUANG-JU ,  ANDERSON COREY ,  SIESEL DAVID ANDREW ,  PIERRE FABRICE JEAN DENIS ,  VAN GOOR FREDRICK F ,  KHATUYA HARIPADA ,  MCCARTNEY JASON ,  CLEMENS JEREMY J ,  ZHOU JINGLAN ,  UY JOHNNY ,  STAVROPOULOS KATHY ,  FERRIS LORI ANN ,  MILLER MARK THOMAS ,  BAEK MINSON ,  SHRESTHA MUNA ,  KRENITSKY PAUL JHON ,  ANGELL PAUL TIMOTHY ,  GROOTENHUIS PETER DIEDIERIK JAN ,  KANG PING ,  JOSHI PRAMOD VIRUPAX ,  PARASELLI PRASUNA ,  GROSS RAYMOND STANLEY ,  HUGHES ROBERT M ,  HADIDA RUAH SARA SABINA ,  CLEVELAND THOMAS ,  ALCACIO TIMOTHY ,  YOUNG TOMOTHY JOHN ,  SHI YI

IPC: C07D401/14 ,  A61K31/455 ,  A61P11/00 ,  C07D231/20 ,  C07D401/04

Abstract: Se describen compuestos de Fórmula (I): (ver fórmulas) sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.

公开(公告)号：CA2975048C

公开(公告)日：2024-01-02

申请号：CA2975048

申请日：2016-01-29

Applicant: BIOMED VALLEY DISCOVERIES INC ,  VERTEX PHARMA

Inventor： DECRESCENZO GARY ,  WELSCH DEAN ,  VLAHOVA PETINKA I ,  BOERRIGTER STEPHAN X M ,  ARONOV ALEXANDER ,  KESHAVARZ-SHOKRI ALI ,  SCANGAS ALEXANDER N ,  STAVROPOULOS KATHY ,  LITTLER BENJAMIN ,  KADIYALA IRINA NIKOLAEVNA ,  ALARGOVA ROSSITZA GUEORGUIEVA

IPC: C07D401/04 ,  A61K31/4439 ,  A61P35/00

Abstract: The present invention provides crystalline forms of a compound of formula (I). Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer. It has been discovered that crystalline forms of 4-(5-Chloro-2- isopropylaminopyridin-4-yl)-1 H-pyrrole-2-carboxylic acid [1 -(3-chlorophenyl)-2- hydroxyethyl]amide can be prepared which exhibit improved properties, e.g. surprisingly improved stability and improved solubility characteristics. Thus, the present invention provides crystalline 4-(5-Chloro-2- isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1 -(3-chlorophenyl)-2- hydroxyethyljamide.

公开(公告)号：AU2023254937A1

公开(公告)日：2023-11-16

申请号：AU2023254937

申请日：2023-10-25

Applicant: BIOMED VALLEY DISCOVERIES INC ,  VERTEX PHARMA

Inventor： DECRESCENZO GARY ,  WELSCH DEAN ,  VLAHOVA PETINKA I ,  BOERRIGTER STEPHAN X M ,  ARONOV ALEXANDER ,  KESHAVARZ-SHOKRI ALI ,  SCANGAS ALEXANDER N ,  STAVROPOULOS KATHY ,  LITTLER BENJAMIN ,  KADIYALA IRINA NIKOLAEVNA

IPC: C07D401/04

Abstract: : The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.